Why Did Warren Buffett Buy More Shares of This Healthcare Company?

In a Form 3 filing issued with the SEC earlier this morning, Warren Buffett’s Berkshire Hathaway Inc. (NYSE:BRK.A) (NYSE:BRK.B) disclosed that it now owns more than 10% of dialysis services provider DaVita Inc. (NYSE:DVA). The move increased Buffett’s total holdings of DaVita to 10.2 million shares, with the most recent transaction amounting to little over 280,000 shares worth $29.7 million. The “Oracle of Omaha” now holds a whopping $1.1 billion in DaVita stock. Here’s a complete look at Warren Buffett’s holdings.

Warren BuffettIn early morning trading following the release, shares of the company were up almost 1.5%. Before you write off these gains as purely speculative, it’s important to remember that empirical studies have proven that individual investors who mimic or “monkey,” the world’s most successful hedge fund managers can beat the market by 7 percentage points a year. Therefore, it’s worth looking into a potential motive behind Buffett’s bullish DaVita bet.

Since the start of 2012, DaVita has been a solid investment, returning 37.8%. This appreciation has outpaced the medical care industry’s average (23.8%), and competitors Baxter International Inc. (NYSE:BAX) at 22.6%, and Fresenius Medical Care AG & Co. (NYSE:FMS) at 10.3%. Over this same time, DaVita has reported generally impressive earnings, beating the Street’s estimates in three straight quarters. This streak is longer than that of Baxter, which has beat analyst forecasts in two straight quarters, but below similarly-sized peers like Fresenius, HCA Holdings Inc (NYSE:HCA), and Tenet Healthcare Corporation (NYSE:THC).

In its most recent earnings release, DaVita reported an EPS of $1.49, beating consensus by 2 cents, even though the company experienced larger than expected second quarter losses related to its international expansion efforts. CEO Kent Thiry called the period “rock-solid,” claiming that his company “perform[ed] well clinically, operationally and strategically.”

Part of DaVita’s international expansion plan includes partnering with medical organizations in Southeast Asia, Europe, and the Middle East to bring affordable dialysis care to patients of all nationalities. Most of the company’s costs related to this activity stems from the legal and professional service fees needed to close the deal on partnerships and acquisitions. These expenses totaled $12 million in the past quarter, and the company expects to lose $30 million by the end of this year, though execs state “international expansion is a long-term growth activity, it will require … continued losses in the short term.”

Most likely, Buffett is optimistic that these expansion plans will help DaVita generate solid earnings appreciation going forward. Early estimates expect the company to average EPS growth of 12.3% a year over the next half-decade. This is decidedly more impressive than its aforementioned competitors, as Baxter (8.5%), Fresenius (10.5%), HCA Holdings (10.9%), and Tenet Healthcare (12.2%) all have lower expected EPS growth.

From a valuation standpoint, we can see that investors are not overpaying for DaVita’s earnings potential, as the company’s stock sports a PEG ratio of 1.54; typically any figure between 1 and 2 indicates shares are trading at a fair price. More interestingly, DaVita is actually cheaper than the likes of Baxter, Fresenius and Tenet Healthcare, which trade at an average PEG of 2.36. Only HCA Holdings, which trades at a PEG of 0.48, is a better value.

One final point worth mentioning is that DaVita appears to have the first step on its competitors due to its advantageous operational efficiency. Over the past twelve months, the company has averaged operating (16.1%) and net (6.9%) margins far above the industry averages (12.4%, 4.3%), indicating that Buffett is most likely a fan of DaVita’s superior cost-saving abilities.

While DaVita is expecting double-digit earnings expansion in a time when the majority of other companies operating in the medical care industry are predicting much less, the biggest reason to be bullish on this stock is that investors can truly buy growth at a reasonable price. Despite DaVita’s gains in 2012 thus far, valuation indicators suggest that more appreciation may be on the horizon, and a boost from Warren Buffett is never a bad thing.

Other fund managers that currently hold DaVita are Andreas Halvorsen’s Viking Global, Stephen Mandel, and Lee Ainslie, though Buffett owns more than twice the number of shares as the next closest fund. For a complete look at the hedge fund industry’s sentiment toward this stock, continue reading here.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!